Varicella Zoster Virus ORF9 (VZV VP22) (AA 6-28), (AA 76-100) Protein

Catalog No. ABIN935888

This Recombinant Varicella Zoster Virus ORF9 protein is produced in Escherichia coli (E. coli).

Quick Overview for Varicella Zoster Virus ORF9 (VZV VP22) (AA 6-28), (AA 76-100) Protein (ABIN935888)

Target: Varicella Zoster Virus ORF9 (VZV VP22)

Protein Type: Recombinant

Origin: Varicella Zoster Virus (VZV)

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), ELISA

Purity: > 95 % pure

Product Details

Protein Characteristics: AA 6-28, AA 76-100

Characteristics: Purified recombinant VZV ORF9 protein
Expression System: E.coli

Purification: Proprietary chromatographic technique

Application Details

Application Notes: Each Investigator should determine their own optimal working dilution for specific applications.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: 25 mM tris-HCl, pH 8.0, with 5 mM EDTA and 50 % glycerol.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Target Details

Target: Varicella Zoster Virus ORF9 (VZV VP22)

Target Type: Viral Protein

Background: VZV is closely related to the herpes simplex viruses (HSV), sharing much genomehomology. The known envelope glycoproteins (gB, gC, gE, gH, gI, gK, gL) correspond with those in HSV, however there is no equivalent of HSV gD. VZV virons are spherical and 150-200 nm in diameter. Their lipidenvelope encloses the nucleocapsid of 162 capsomeres arranged in a hexagonalform. Its DNAis a single, linear, double-stranded molecule, 125,000 nt long. The virus is very susceptible to disinfectants, notably sodium hypochlorite. Within the body it can be treated by a number of drugs and therapeutic agents including aciclovir, zoster-immune globulin (ZIG), and vidarabine.
Alternative Names: Varicella Zoster Virus ORF9 protein